Trump blasts Pfizer price hikes, pledges a governmental resp

Industry news | 11 July, 2018 | CACLP

President Donald Trump is trying to shame the largest U.S. drugmaker for hiking prices after he earlier said industry players were planning "massive" price reductions. He said Pfizer and others "should be ashamed that they have raised drug prices for no reason" while suggesting some unspecified retaliation.

Pfizer & others should be ashamed that they have raised drug prices for no reason. They are merely taking advantage of the poor & others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe & elsewhere. We will respond!

— Donald J. Trump (@realDonaldTrump) July 9, 2018

A Pfizer spokesperson said the company markets more than 400 drugs and vaccines, and recently modified prices on about 10% of its portfolio, including some price reductions. List prices don't typically reflect what patients or insurers pay, he added. Reiterating a popular drug industry complaint, Pfizer's representative pointed out that net prices grew 0% in the first quarter "due to the growing amount of rebates paid back to stakeholders in the biopharmaceutical supply chain."

Pfizer's shares were trading slightly up in midafternoon trading after the tweet.

President Trump's tweet comes only days after reports that Pfizer raised prices on dozens of drugs starting in July, with many increases coming in at 9%. Before the reports, Trump said in late May that drugmakers were planning "massive" voluntary price cuts.

In a note before the president's tweet on Monday, Bernstein analyst Ronny Gal said Trump's price reduction statement caught HHS officials off guard. According to the analyst, HHS in response has asked companies to cut list prices without the expectation that net prices would come down.

Now, the president is taking his argument to the public.

Pfizer can take solace that it's not the only drug maker—or large company—to attract the president's ire on Twitter. After Merck CEO Ken Frazier left the president's manufacturing council last summer in the wake of Trump's equivocal response to white supremacist violence, Trump tweeted that the helmsman would have more time to "lower rip off drug prices." Trump has additionally weighed in on fighter jet prices, Amazon's tax situation and more.

Pfizer also isn't alone in raising its drug prices during the Trump administration. Pfizer's July price hikes were its second round this year after the industry's standard round of increases in January. In a January note, Wells Fargo analyst David Maris outlined price hikes from Pfizer, AstraZeneca, Novartis, Eli Lilly, Sanofi and more. AbbVie's 9.7% price hike on Humira will cost the U.S. health system $1.2 billion this year, the analyst predicted.

At the same time, many industry players have committed to limiting their hikes amid a yearslong examination of pharmaceutical pricing. Allergan and AbbVie are among companies that have pledged to keep price hikes to once per year and under 10%.

Sanofi has said it will keep its price hikes to the rate of medical inflation. Pfizer has not implemented such restrictions to pricing.

After a round of increases last year, members of the Interfaith Center on Corporate Responsibility wrote to Pfizer CEO Ian Read to say they're worried the company "has responded to the intense scrutiny on pricing over the past year by continuing a relentless march forward on drug price increases." In the letter, ICCR investor members said they believe Pfizer is “increasingly out of step with leaders in the sector.”

A company spokesperson declined to respond to the letter but reiterated a statement that the company "has always priced responsibly" and that it believes "innovative medicines are one of the most valuable and cost-effective segments of healthcare spend and are an important part of the solution to growing healthcare costs."

Even as President Trump has blasted industry pricing, his administration granted drug makers a boost at the end of 2017 with tax reform. Surrounding the passage of tax reform, drug makers have implemented tens of billions of share buybacks as drug prices have continued to climb.

In April, Sen. Cory Booker, D-N.J., argued companies could have used the savings to lower prices. Instead, the senator noted in a report, Pfizer, Merck, AbbVie, Amgen and Celgene kicked off share buybacks worth $45 billion before or after passage of the tax law. Companies have also announced new manufacturing and R&D investments, boosts to nonexecutive compensation, charitable gifts and more as a result of tax reform.

Filed under：

Press contact

CACLP - The largest IVD Expo & Conference

Back to list

Stay in touch with CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News, sign-up for our newsletter today.

Name *
Email *
Company name *
Country *

By subscribing our newsletter, you agree to our Privacy Policy. You can unsubscribe at anytime.

Room 2201-2203 & 2205, Cloud Nine Plaza
1118 West Yan’an Road
Shanghai, China
200052

Visit Exhibit Conferences Webinars Newsroom About Us FAQs

We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy & Cookies for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

No, thanks. Yes, I agree.

Subscribe to CACLP News

We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.

Name *
Email *
Telephone
Job title
Company name *
Country *

By submitting the form here, you agree to our Privacy Policy and agree that we may store and access the information you provide.

Trump blasts Pfizer price hikes, pledges a governmental resp

Most popular

Quest Diagnostics Launches Health Coaching on questhealth.com to Help Individuals Take Control of Their Health

A. Menarini Diagnostics and Sinocare Announce Exclusive Distribution Agreement for New Continuous Glucose Monitoring System

In Vitro Diagnostic Industry in China - Molecular Diagnosis Analyzers and Reagents IX

Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint

Devyser achieves Class D IVDR approval for its RHD product

Stay in touch with CACLP News

Subscribe to CACLP News

Thank you for subscribing to CACLP News!